Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires CRO; Set for First Tirzepatide Molecule Study
Lexaria, a global innovator in drug delivery platforms, recently announced the hiring of a Contract Research Organization (“CRO”) for its third human pilot study The study, a randomized, crossover investigation, will evaluate a dual-action glucagon-like peptide 1 (“GLP-1”) + glucose-dependent insulintropic peptide (“GIP”) It will measure absorption, tolerability, pharmacokinetics, and blood sugar levels Lexaria is counting on its patented DehydraTECH technology for significant growth in the 2024 calendar year, and the study reflects this commitment Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the hiring of a Contract Research Organization (“CRO”) for its third human…